BIOCARTIS news, videos and press releases - Page 3
For more news please use our advanced search feature.
BIOCARTIS - More news...
BIOCARTIS - More news...
- Press release Biocartis Group NV: BIOCARTIS Q1 2021 BUSINESS UPDATE
- Press release Biocartis Group NV: Invitation to the Annual and Extraordinary Shareholders’ Meetings
- Press release Biocartis Group NV: BIOCARTIS ANNOUNCES 2020 RESULTS AND 2021 OUTLOOK
- Press news Biocartis Group NV: BIOCARTIS ANNOUNCES 2020 FULL YEAR RESULTS ON 25 FEBRUARY 2021
- Press news Biocartis Group NV: New US Studies Demonstrate Idylla™ Allows Rapid First Assessment of Most Common EGFR Mutations Preceding Next-Generation Sequencing
- Press news Biocartis Group NV: BIOCARTIS MEETS 2020 KEY OBJECTIVES
- Press news Biocartis Group NV: DISCLOSURE OF OUTSTANDING VOTING SECURITIES
- Press news Biocartis Group NV: Biocartis Announces the Conversion of EUR 15 million of its EUR 150 million 4% Convertible Bonds due 2024
- Press news Biocartis Group NV: Biocartis Announces Publication of Large Multi-Center Comparison Study with Idylla™ MSI Assay Showing Very Low Failure Rates and Excellent Concordance with Reference Methods
- Press news Biocartis Group NV: Biocartis and GeneproDx To Collaborate on Fully Automated ThyroidPrint® test on Idylla™
- Press news Biocartis Group NV: Update on the partnership with Exact Sciences
- Large Prospective Lung Cancer Study To Be Presented at ESMO Congress Shows Idylla™ Reduces EGFR Mutation Testing Turnaround Time by More than a Week, Allowing Faster Patient Management Decisions
- Press news Biocartis Group NV: BIOCARTIS ANNOUNCES H1 2020 RESULTS
- Press news Biocartis Group NV: Biocartis Expands Collaboration with LifeArc
- BIOCARTIS ANNOUNCES 2020 HALF-YEAR RESULTS ON 3 SEPTEMBER 2020
- Press release Biocartis Group NV: Invitation to the Extraordinary Shareholders’ Meeting
- Press release Biocartis Group NV: US Multicenter Study Shows Idylla™ Allows Rapid and Accurate Mutation Testing Results Across Different Laboratory Settings
- Press release Biocartis Group NV: Results of the Shareholders’ Meetings held on 8 May 2020
- Press Release Biocartis Group NV: Biocartis Q1 2020 Business Update
- Press Release Biocartis Group NV: Biocartis Announces Development of Idylla™ COVID-19 test
- Press Release Biocartis Group NV: Biocartis Announces Publication of 2019 Annual Report
- Biocartis Announces New Immuno-Oncology Project with Bristol-Myers Squibb Aimed at Registration of Idylla™ MSI test in China
- Press release Biocartis Group: Biocartis Enters into Master Collaboration Agreement with AstraZeneca and Initiates EGFR Liquid Biopsy Study
- Press Release Biocartis NV: Disclosure of a transparency notification
- Press release Biocartis Group NV: LISTING OF THE EUR 150 MILLION SENIOR UNSECURED CONVERTIBLE BONDS DUE 9 MAY 2024
- Press release Biocartis Group NV: BIOCARTIS Q3 2019 BUSINESS UPDATE
- Press release Biocartis Group NV: NICHIREI BIOSCIENCES TO INITIATE MARKET INTRODUCTION OF IDYLLA™ PLATFORM IN JAPAN
- Press news Biocartis Group NV: Disclosure of a transparency notification
- Press release Biocartis NV.: Biocartis Launches Liquid Biopsy Idylla™ ctEGFR Mutation Assay
- Press Release Biocartis NV: Biocartis announces H1 2019 results
